Monthly Archives: March 2018
The short course “Basics of AO technologies and applications in VioBio Lab”, directed by Dr. Maria Viñas and sponsored by CSIC posgraduate studies kicks off today in Madrid. The course will review from a practical perspective the developments and applications of Adaptive Optics Technologies addressed in VioBio and beyond. Attendees will be VioBio Lab members developing research work in AO visual simulation and retinal imaging, and students considering research and/or clinical work in this area
Course program here.
More information on CSIC specialization courses: http://www.csic.es/cursos-de-postgrado
The patent protecting “Miniaturized Simultaneous Vision Simulator” technology was awarded yesterday with the Best Patent Prize by Fundación Madri+d. The award acknowledges the quality of the technology and the high market potential. The patent is granted in the US and Europe and licensed, along with three others owned by CSIC, to the spin-off company 2EyesVision.
Carlos Dorronsoro picked up the award on behalf of the co-inventors.
– Press release by CSIC
– More information about the patent’s technology here.
Position for Research and Development Specialist (experience in managing innovation and new product development in relation with the ophthalmic industry) is open at VIOBIO Lab (Instituto de Óptica, CSIC). The position is funded by the European Commission in the framework of the “Light AIOL” ERC-Proof of Concept project.
See full profile and contact details in the next link:
The kick-off meeting of the H2020 Innovation Action IMCUSTOMEYE has taken place this week at CSIC led by Prof. Susana Marcos, researcher of the Institute of Optics (CSIC).
The IMCUSTOMEYE project will develop a new optical imaging system that will allow to obtain biomarkers to improve diagnosis of certain ocular pathologies such as glaucoma and keratoconus, and the development of customize treatments such as refractive surgery, cataract surgery and corneal treatments. Nowadays the diagnosis of corneal conditions and the selection of patients for refractive surgery are performed based on purely morphological effects (asymmetries in the cornea, corneal thickness). The new instrument will provide biomechanical parameters, which will allow to plan treatments based on the prediction of the corneal response (for example, to incisions or corneal implants). IMCUSTOMEYE will develop new diagnostic paradigms for these vision-threatening conditions.
The IMCUSTOMEYE consortium consists of 10 partners, from 6 different countries and different fields, academic, clinical and industrial: National University of Ireland, Polish Academy of Science, University of Liverpool, University College London-Moorfields Eye Hospital, Oculus Gmbh, 2EyesVision SL, IROC Science, Optimo Medical AG. During the kick-off meeting the partners presented their research activities and expected contributions to the project, and hold 10 round table discussions on technical aspects of the project, IP handling, and commercialization, among others.